Cummings AL, Sussell J, Rosettie KL, Moustaid FE, et al. A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer. Lung Cancer 2025;207:108701.
PMID: 40811940